Participated in Leal Therapeutics' $30M Series A financing for neuro-metabolic CNS therapeutics.
Leal Therapeutics is developing novel, first-in-class, neuro-metabolic therapeutics for high unmet need CNS disorders, focusing on correcting key metabolic imbalances that underlie neuropsychiatric and neurodegenerative disorders
Leal Therapeutics is developing novel, first-in-class, neuro-metabolic therapeutics for high unmet need CNS disorders, focusing on correcting key metabolic imbalances that underlie neuropsychiatric and neurodegenerative disorders.